<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">28413671</PMID>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">2049-9450</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>6</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular and clinical oncology</Title>
          <ISOAbbreviation>Mol Clin Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic limbic encephalitis in a patient with extensive disease small-cell lung cancer.</ArticleTitle>
        <Pagination>
          <StartPage>575</StartPage>
          <EndPage>578</EndPage>
          <MedlinePgn>575-578</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/mco.2017.1162</ELocationID>
        <Abstract>
          <AbstractText>Paraneoplastic limbic encephalitis (PLE) is a rare disorder infrequently accompanying malignancy, coexisting in ~50% of the cases with small-cell lung cancer (SCLC). The pathomechanism of PLE is considered to be immune-mediated, with production of specific anti-Hu antibodies and activation of T-cells directed against onconeural antigens present on both tumor cells and neurons. We herein report the case of a 50-year-old male patient who, prior to being diagnosed with SCLC, presented with typical symptoms of PLE (seizures, subacute cognitive dysfunction with severe memory impairment, anxiety and hallucinations). The initial brain magnetic resonance imaging examination revealed mild enlargement and hyperintensity of the hippocampal gyri bilaterally, with narrowed temporal horns of the lateral ventricles; the findings of the cerebrospinal fluid examination were compatible with the diagnosis of lymphocytic meningitis. Due to the suspected infectious origin of the disease, treatment with acyclovir and antibiotics was initially applied. However, following subsequent diagnosis of the underlying SCLC and the presence of antineuronal anti-Hu antibodies in the patient's serum, the diagnosis of PLE accompanying extensive-disease (ED) SCLC was confirmed. In addition to the standard cytotoxic therapy, throughout the course of his disease the patient also continued treatment with valproic acid (VPA) as prophylaxis for the initial seizures. VPA is known to be a potent histone deacetylase inhibitor that may reverse epigenetic changes in tumor cells and potentially improve the outcome of cancer patients. The patient succumbed to the disease 25 months after the diagnosis of malignancy; such a long course is observed in only ~5% of patients with ED SCLC. Therefore, it was hypothesized that the accompanying paraneoplasia and treatment with VPA may have improved the outcome in this patient.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ochenduszko</LastName>
            <ForeName>Sebastian</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University Hospital in Krakow, 31-531 Krakow, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wilk</LastName>
            <ForeName>Bartosz</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Medical University of Silesia Hospital No. 7, Professor Leszek Giec Upper Silesian Medical Centre, 40-635 Katowice, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dabrowska</LastName>
            <ForeName>Joanna</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University Hospital in Krakow, 31-531 Krakow, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Herman-Sucharska</LastName>
            <ForeName>Izabela</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Electroradiology, Jagiellonian University Medical College, 31-126 Krakow, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dubis</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Electroradiology, Jagiellonian University Medical College, 31-126 Krakow, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Puskulluoglu</LastName>
            <ForeName>Miroslawa</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Jagiellonian University Medical College, 31-531 Krakow, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>02</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Clin Oncol</MedlineTA>
        <NlmUniqueID>101613422</NlmUniqueID>
        <ISSNLinking>2049-9450</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">anti-Hu antibodies</Keyword>
        <Keyword MajorTopicYN="N">chemotherapy</Keyword>
        <Keyword MajorTopicYN="N">paraneoplastic limbic encephalitis</Keyword>
        <Keyword MajorTopicYN="N">small-cell lung cancer</Keyword>
        <Keyword MajorTopicYN="N">synergistic effect</Keyword>
        <Keyword MajorTopicYN="N">valproic acid</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>11</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28413671</ArticleId>
        <ArticleId IdType="pmc">PMC5374934</ArticleId>
        <ArticleId IdType="doi">10.3892/mco.2017.1162</ArticleId>
        <ArticleId IdType="pii">MCO-0-0-1162</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi: 10.3322/caac.21262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21262</ArticleId>
            <ArticleId IdType="pubmed">25651787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puglisi M, Dolly S, Faria A, Myerson JS, Popat S, O'Brien ME. Treatment options for small cell lung cancer-do we have more choice? Br J Cancer. 2010;102:629–638. doi: 10.1038/sj.bjc.6605527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6605527</ArticleId>
            <ArticleId IdType="pmc">PMC2837580</ArticleId>
            <ArticleId IdType="pubmed">20104223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amini A, Byers LA, Welsh JW, Komaki RU. Progress in the management of limited-stage small cell lung cancer. Cancer. 2014;120:790–798. doi: 10.1002/cncr.28505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.28505</ArticleId>
            <ArticleId IdType="pmc">PMC3947683</ArticleId>
            <ArticleId IdType="pubmed">24327434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bataller L, Dalmau J. Paraneoplastic neurologic syndromes. Neurol Clin. 2003;21:221–247, ix. doi: 10.1016/S0733-8619(02)00037-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0733-8619(02)00037-3</ArticleId>
            <ArticleId IdType="pubmed">12690651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: Neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123:1481–1494. doi: 10.1093/brain/123.7.1481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/123.7.1481</ArticleId>
            <ArticleId IdType="pubmed">10869059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altman AJ, Baehner RL. Favorable prognosis for survival in children with coincident opso-myoclonus and neuroblastoma. Cancer. 1976;37:846–852. doi: 10.1002/1097-0142(197602)37:2&lt;846::AID-CNCR2820370233&gt;3.0.CO;2-L.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1097-0142(197602)37:2&lt;846::AID-CNCR2820370233&gt;3.0.CO;2-L</ArticleId>
            <ArticleId IdType="pubmed">1253109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet. 1999;353:117–118. doi: 10.1016/S0140-6736(05)76153-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(05)76153-5</ArticleId>
            <ArticleId IdType="pubmed">10023900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Dalmou J, Reñé R, Tora M, Malats N, Verschuuren JJ, Cardenal F, Viñolas N, del Muro J Garcia, Vadell C, et al.  Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival. J Clin Oncol. 1997;15:2866–2872. doi: 10.1200/JCO.1997.15.8.2866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.1997.15.8.2866</ArticleId>
            <ArticleId IdType="pubmed">9256130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altan M, Chiang AC. Management of small cell lung cancer: Progress and Updates. Cancer J. 2015;21:425–433. doi: 10.1097/PPO.0000000000000148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PPO.0000000000000148</ArticleId>
            <ArticleId IdType="pubmed">26389768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hubaux R, Vandermeers F, Crisanti MC, Kapoor V, Burny A, Mascaux C, Albelda SM, Willems L. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy. Eur J Cancer. 2010;46:1724–1734. doi: 10.1016/j.ejca.2010.03.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2010.03.021</ArticleId>
            <ArticleId IdType="pubmed">20451370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hubaux R, Vandermeers F, Cosse JP, Crisanti C, Kapoor V, Albelda S, Mascaux C, Delvenne P, Hubert P, Willems L. Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models. ERJ Open Res. 2015;1:00028–2015. doi: 10.1183/23120541.00028-2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/23120541.00028-2015</ArticleId>
            <ArticleId IdType="pmc">PMC5005116</ArticleId>
            <ArticleId IdType="pubmed">27730151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alamowitch S, Graus F, Uchuya M, Reñé R, Bescansa E, Delattre JY. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain. 1997;120:923–928. doi: 10.1093/brain/120.6.923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/120.6.923</ArticleId>
            <ArticleId IdType="pubmed">9217677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman NJ, Bell IR, McKee AC. Paraneoplastic limbic encephalitis: Neuropsychiatric presentation. Biol Psychiatry. 1990;27:529–542. doi: 10.1016/0006-3223(90)90444-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-3223(90)90444-7</ArticleId>
            <ArticleId IdType="pmc">PMC7111189</ArticleId>
            <ArticleId IdType="pubmed">2155672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakheit AM, Kennedy PG, Behan PO. Paraneoplastic limbic encephalitis: Clinico-pathological correlations. J Neurol Neurosurg Psychiatry. 1990;53:1084–1088. doi: 10.1136/jnnp.53.12.1084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.53.12.1084</ArticleId>
            <ArticleId IdType="pmc">PMC488321</ArticleId>
            <ArticleId IdType="pubmed">1963440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7:327–340. doi: 10.1016/S1474-4422(08)70060-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(08)70060-7</ArticleId>
            <ArticleId IdType="pmc">PMC2367117</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demaerel P, Wilms G, Robberecht W, Johannik K, Van Hecke P, Carton H, Baert AL. MRI of herpes simplex encephalitis. Neuroradiology. 1992;34:490–493. doi: 10.1007/BF00598957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00598957</ArticleId>
            <ArticleId IdType="pubmed">1436457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543–1554. doi: 10.1056/NEJMra023009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra023009</ArticleId>
            <ArticleId IdType="pubmed">14561798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY. Anti-Hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain. 2001;124:1138–1148. doi: 10.1093/brain/124.6.1138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/124.6.1138</ArticleId>
            <ArticleId IdType="pubmed">11353730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev. 2008;34:206–222. doi: 10.1016/j.ctrv.2007.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2007.11.003</ArticleId>
            <ArticleId IdType="pubmed">18226465</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">28413671</PMID>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">2049-9450</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>6</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular and clinical oncology</Title>
          <ISOAbbreviation>Mol Clin Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic limbic encephalitis in a patient with extensive disease small-cell lung cancer.</ArticleTitle>
        <Pagination>
          <StartPage>575</StartPage>
          <EndPage>578</EndPage>
          <MedlinePgn>575-578</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/mco.2017.1162</ELocationID>
        <Abstract>
          <AbstractText>Paraneoplastic limbic encephalitis (PLE) is a rare disorder infrequently accompanying malignancy, coexisting in ~50% of the cases with small-cell lung cancer (SCLC). The pathomechanism of PLE is considered to be immune-mediated, with production of specific anti-Hu antibodies and activation of T-cells directed against onconeural antigens present on both tumor cells and neurons. We herein report the case of a 50-year-old male patient who, prior to being diagnosed with SCLC, presented with typical symptoms of PLE (seizures, subacute cognitive dysfunction with severe memory impairment, anxiety and hallucinations). The initial brain magnetic resonance imaging examination revealed mild enlargement and hyperintensity of the hippocampal gyri bilaterally, with narrowed temporal horns of the lateral ventricles; the findings of the cerebrospinal fluid examination were compatible with the diagnosis of lymphocytic meningitis. Due to the suspected infectious origin of the disease, treatment with acyclovir and antibiotics was initially applied. However, following subsequent diagnosis of the underlying SCLC and the presence of antineuronal anti-Hu antibodies in the patient's serum, the diagnosis of PLE accompanying extensive-disease (ED) SCLC was confirmed. In addition to the standard cytotoxic therapy, throughout the course of his disease the patient also continued treatment with valproic acid (VPA) as prophylaxis for the initial seizures. VPA is known to be a potent histone deacetylase inhibitor that may reverse epigenetic changes in tumor cells and potentially improve the outcome of cancer patients. The patient succumbed to the disease 25 months after the diagnosis of malignancy; such a long course is observed in only ~5% of patients with ED SCLC. Therefore, it was hypothesized that the accompanying paraneoplasia and treatment with VPA may have improved the outcome in this patient.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ochenduszko</LastName>
            <ForeName>Sebastian</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University Hospital in Krakow, 31-531 Krakow, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wilk</LastName>
            <ForeName>Bartosz</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Medical University of Silesia Hospital No. 7, Professor Leszek Giec Upper Silesian Medical Centre, 40-635 Katowice, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dabrowska</LastName>
            <ForeName>Joanna</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University Hospital in Krakow, 31-531 Krakow, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Herman-Sucharska</LastName>
            <ForeName>Izabela</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Electroradiology, Jagiellonian University Medical College, 31-126 Krakow, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dubis</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Electroradiology, Jagiellonian University Medical College, 31-126 Krakow, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Puskulluoglu</LastName>
            <ForeName>Miroslawa</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Jagiellonian University Medical College, 31-531 Krakow, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>02</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Clin Oncol</MedlineTA>
        <NlmUniqueID>101613422</NlmUniqueID>
        <ISSNLinking>2049-9450</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">anti-Hu antibodies</Keyword>
        <Keyword MajorTopicYN="N">chemotherapy</Keyword>
        <Keyword MajorTopicYN="N">paraneoplastic limbic encephalitis</Keyword>
        <Keyword MajorTopicYN="N">small-cell lung cancer</Keyword>
        <Keyword MajorTopicYN="N">synergistic effect</Keyword>
        <Keyword MajorTopicYN="N">valproic acid</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>11</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28413671</ArticleId>
        <ArticleId IdType="pmc">PMC5374934</ArticleId>
        <ArticleId IdType="doi">10.3892/mco.2017.1162</ArticleId>
        <ArticleId IdType="pii">MCO-0-0-1162</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi: 10.3322/caac.21262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21262</ArticleId>
            <ArticleId IdType="pubmed">25651787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puglisi M, Dolly S, Faria A, Myerson JS, Popat S, O'Brien ME. Treatment options for small cell lung cancer-do we have more choice? Br J Cancer. 2010;102:629–638. doi: 10.1038/sj.bjc.6605527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6605527</ArticleId>
            <ArticleId IdType="pmc">PMC2837580</ArticleId>
            <ArticleId IdType="pubmed">20104223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amini A, Byers LA, Welsh JW, Komaki RU. Progress in the management of limited-stage small cell lung cancer. Cancer. 2014;120:790–798. doi: 10.1002/cncr.28505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.28505</ArticleId>
            <ArticleId IdType="pmc">PMC3947683</ArticleId>
            <ArticleId IdType="pubmed">24327434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bataller L, Dalmau J. Paraneoplastic neurologic syndromes. Neurol Clin. 2003;21:221–247, ix. doi: 10.1016/S0733-8619(02)00037-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0733-8619(02)00037-3</ArticleId>
            <ArticleId IdType="pubmed">12690651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: Neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123:1481–1494. doi: 10.1093/brain/123.7.1481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/123.7.1481</ArticleId>
            <ArticleId IdType="pubmed">10869059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altman AJ, Baehner RL. Favorable prognosis for survival in children with coincident opso-myoclonus and neuroblastoma. Cancer. 1976;37:846–852. doi: 10.1002/1097-0142(197602)37:2&lt;846::AID-CNCR2820370233&gt;3.0.CO;2-L.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1097-0142(197602)37:2&lt;846::AID-CNCR2820370233&gt;3.0.CO;2-L</ArticleId>
            <ArticleId IdType="pubmed">1253109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet. 1999;353:117–118. doi: 10.1016/S0140-6736(05)76153-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(05)76153-5</ArticleId>
            <ArticleId IdType="pubmed">10023900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Dalmou J, Reñé R, Tora M, Malats N, Verschuuren JJ, Cardenal F, Viñolas N, del Muro J Garcia, Vadell C, et al.  Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival. J Clin Oncol. 1997;15:2866–2872. doi: 10.1200/JCO.1997.15.8.2866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.1997.15.8.2866</ArticleId>
            <ArticleId IdType="pubmed">9256130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altan M, Chiang AC. Management of small cell lung cancer: Progress and Updates. Cancer J. 2015;21:425–433. doi: 10.1097/PPO.0000000000000148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PPO.0000000000000148</ArticleId>
            <ArticleId IdType="pubmed">26389768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hubaux R, Vandermeers F, Crisanti MC, Kapoor V, Burny A, Mascaux C, Albelda SM, Willems L. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy. Eur J Cancer. 2010;46:1724–1734. doi: 10.1016/j.ejca.2010.03.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2010.03.021</ArticleId>
            <ArticleId IdType="pubmed">20451370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hubaux R, Vandermeers F, Cosse JP, Crisanti C, Kapoor V, Albelda S, Mascaux C, Delvenne P, Hubert P, Willems L. Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models. ERJ Open Res. 2015;1:00028–2015. doi: 10.1183/23120541.00028-2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/23120541.00028-2015</ArticleId>
            <ArticleId IdType="pmc">PMC5005116</ArticleId>
            <ArticleId IdType="pubmed">27730151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alamowitch S, Graus F, Uchuya M, Reñé R, Bescansa E, Delattre JY. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain. 1997;120:923–928. doi: 10.1093/brain/120.6.923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/120.6.923</ArticleId>
            <ArticleId IdType="pubmed">9217677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman NJ, Bell IR, McKee AC. Paraneoplastic limbic encephalitis: Neuropsychiatric presentation. Biol Psychiatry. 1990;27:529–542. doi: 10.1016/0006-3223(90)90444-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-3223(90)90444-7</ArticleId>
            <ArticleId IdType="pmc">PMC7111189</ArticleId>
            <ArticleId IdType="pubmed">2155672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakheit AM, Kennedy PG, Behan PO. Paraneoplastic limbic encephalitis: Clinico-pathological correlations. J Neurol Neurosurg Psychiatry. 1990;53:1084–1088. doi: 10.1136/jnnp.53.12.1084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.53.12.1084</ArticleId>
            <ArticleId IdType="pmc">PMC488321</ArticleId>
            <ArticleId IdType="pubmed">1963440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7:327–340. doi: 10.1016/S1474-4422(08)70060-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(08)70060-7</ArticleId>
            <ArticleId IdType="pmc">PMC2367117</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demaerel P, Wilms G, Robberecht W, Johannik K, Van Hecke P, Carton H, Baert AL. MRI of herpes simplex encephalitis. Neuroradiology. 1992;34:490–493. doi: 10.1007/BF00598957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00598957</ArticleId>
            <ArticleId IdType="pubmed">1436457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543–1554. doi: 10.1056/NEJMra023009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra023009</ArticleId>
            <ArticleId IdType="pubmed">14561798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY. Anti-Hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain. 2001;124:1138–1148. doi: 10.1093/brain/124.6.1138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/124.6.1138</ArticleId>
            <ArticleId IdType="pubmed">11353730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev. 2008;34:206–222. doi: 10.1016/j.ctrv.2007.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2007.11.003</ArticleId>
            <ArticleId IdType="pubmed">18226465</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
